Heron Therapeutics, Inc. (NASDAQ: HRTX) is a biotechnology
company focused on the development and commercialization of best-in-class
pharmaceutical products that address major unmet medical needs. The company’s
leading drug candidate, SUSTOL®, is being developed for the prevention of both
acute and delayed chemotherapy-induced nausea and vomiting (CINV), which affects
approximately 75 percent of patients undergoing cancer treatment.
SUSTOL improves upon the current treatment options for CINV
by utilizing Heron’s proprietary drug delivery platform, Biochronomer®. The
company’s groundbreaking delivery technologies allow for sustained levels of
drugs in systemic circulation, providing prolonged efficacy in a variety of
potential applications. In clinical studies, Heron has demonstrated these
benefits, with SUSTOL maintaining therapeutic drug levels for up to five days with
a single subcutaneous injection.
In recent months, the company has taken significant steps
toward the eventual commercialization of SUSTOL. In May, Heron announced the
top-line results from its 900 patient phase III clinical study of the product
candidate. According to these results, SUSTOL provided significantly higher
rates of complete response than the test’s three-drug standard of care
comparator group, demonstrating the overall efficacy and market potential of
the candidate.
“[T]he results… further demonstrate the potential for SUSTOL
to be the foundation of the new standard-of-care injectable anti-emetic
regimen,” Barry D. Quart, chief executive officer of Heron, stated in a news
release. “[W]e are planning for the commercial launch of SUSTOL, pending FDA
approval.”
In addition to its progress with SUSTOL, Heron has also
taken significant steps in the development of its second drug candidate,
HTX-011, in recent weeks. Earlier this month, the company announced the
initiation of a phase II clinical trial on the candidate for the prevention of
post-operative pain. By effectively assisting patients in managing pain with a
reduction in the use of opioids, as compared to the current standard of care,
HTX-011 could provide Heron with an additional platform to realize continued
growth in the future.
“We believe that HTX-011 has the potential to meet our core
goal of developing best-in-class medicines with the potential to significantly
improve the lives of patients,” continued Quart.
For prospective investors, Heron’s rapid progress toward the
commercialization of its two leading drug candidates could provide a platform
to realize substantial returns in the years to come.
For more information, visit www.herontx.com
About
MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
